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Abstract 
Introduction: Apolipoprotein E (APOE) encoded by APOE gene is an important lipid 
transport molecule in the central nervous system. Carrying at least one APOE4 allele is the 
strongest known genetic risk factor for the sporadic Alzheimer’s Disease (AD). APOE 
isoforms can differentially influence the AD pathogenesis by affecting the synthesis and 
clearance of the Aβ as well as affecting the neurons independently of the Aβ, for instance 
by disrupting the mitochondria or cytoskeleton and leading to neurodegeneration and 
defective repair. TOMM40 is another gene that have been implicated in AD. Due to its close 
proximity to the APOE gene, it is thought to be in linkage disequilibrium with the APOE 
gene and therefore influence its transcription. APOE genotype could also have an effect on 
the methylation levels, as the 2 SNPs that account for the 3 APOE isoforms, either disrupt 
or create a CpG site- Rs7412 (C->T) removes a CpG site, whereas rs429358 (T->C) creates an 
extra CpG site. Previous studies suggested that methylation of the TOMM40-APOE locus 
may influence the APOE protein levels and thus associate with AD pathology. However, it is 
not fully understood how these genes are transcriptionally regulated. 
Aims: The main aim of this study was to investigate APOE methylation levels and protein 
expression in a number of aged (n=32) and AD (n=30) human brains and to test if the gene 
methylation and protein levels associate with the AD pathology. 
Methods: APOE protein levels were estimated using an ELISA. Genotyping was performed 
using Sequenom MassARRAY iPLEX platform. DNA methylation levels were measured using 
bisulphite pyrosequencing. Prefrontal cortex samples were stained with rabbit APOE 
polyclonal antibody and co-stained with mouse Glial Fibrillary Acidic Protein (GFAP) 
antibody (astrocyte marker) and visualised under fluorescent microscope. 
Results: As expected, the number of APOE4 carriers was significantly higher in the AD 
group. APOE genotype did not have an effect on the TOMM40-APOE locus methylation, nor 
on the APOE protein expression. APOE protein levels were not significantly associated with 
AD pathology. TOMM40 CpG2 negatively correlated with APOE protein levels (r=-0.270, 
P=0.042), however the association was no longer significant after adjustment for 
confounding factors. Methylation of the remaining CpG sites did not correlate with APOE 
protein expression. TOMM40-APOE locus methylation levels did not significantly associate 
with AD pathology. APOE protein levels positively correlated with longitudinal fluid 
intelligence, which in turn were negatively associated with Thal score.  
Conclusion: TOMM40-APOE locus methylation may not be affected by the genotype and 
the methylation levels do not have a direct effect on the AD pathology. APOE protein levels 
may have a domain-specific effect in the prefrontal cortex affecting longitudinal fluid 
intelligence. Further research, preferably in a larger sample group, is necessary to 
investigate the role of the TOMM40-APOE locus methylation in the AD pathology.  
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1. Introduction 
1.1 Dementia and Alzheimer’s disease overview (epidemiology and risk 
factors) 
It is estimated that in the UK, 1 in 14 people at the age over 65 suffer from 
dementia (Prince et al., 2014). As the life expectancy increases, the number of 
people affected by dementia is estimated to grow in the next decades, from over 
850 000 in 2018 to over 2 million in 2050 (Prince et al., 2014). Women have higer 
life expectancy, therefore also a notably higher disease prevalence in older age 
group. As the numbers of the affected people increases, it imposes a great burden 
of the healthcare services and the caregivers. Since the beginning of 2017, 
dementia has overtaken heart disease as a leading cause of death in the UK. 
Dementia is currently incurable and the treatments available have limited success 
in slowing progression of the disease and reducing the symptoms. Alzheimer’s 
disease (AD) is a the most common cause of dementia, accounting for 60-70% of all 
cases (Burns and Iliffe, 2009). Familial AD is very rare form, inherited in autosomal 
dominant manner with an early age of onset. Studies on familial AD (FAD), revealed 
that mutations in APP and components responsible for γ- secretase activity, such as 
presenilin 1 (PSEN1) and PSEN2 are crucial in the Aβ aggregation (Selkoe and 
Kopan, 2003). Sporadic AD, on the other hand, is very common, making up over 
95% of all AD cases (Masters et al., 2015). The onset of sporadic AD is typically late 
and its cause is unknown, probably due to the heterogeneity of the disease. The 
main causes of sporadic AD are ageing, together with an intricate interaction 
between genetic and environmental risk factors. Some of the proposed 
environmental risk factors include lower reserve capacity of the brain, such as 
reduced brain size, low educational and occupational attainment, low mental ability 
in early life and reduced mental and physical activity during late life (Mayeux, 2003; 
Mortimer et al., 2003). The brain reserve capacity is defined by the number of 
neurons and the dendritic and synaptic connections combined with learning 
strategies associated with particular lifestyle (Mayeux, 2003). Certain studies have 
also shown that head injury can be a potential risk factor, however it is not clear 
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whether it directly influences the pathogenesis resulting in plaque and tangle 
formation or plainly reduces the brain reserve (Jellinger, 2004). Risk factors 
associated with vascular disease, such as hypercholesterolemia, hypertension, 
atherosclerosis, smoking, obesity and diabetes may also play a role; although, it is 
unclear whether they directly influence the pathogenesis or, by inducing 
cerebrovascular pathology, they accelerate the onset of clinically silent disease 
(Mayeux, 2003). Some studies suggest that vitamin B and folate, antioxidants (e.g. 
vitamin C and E), unsaturated fatty acids and even moderate alcohol intake may 
have protective effect, however there is not enough evidence for these to be 
recommended as a method of prevention (Luchsinger and Mayeux, 2004). Even 
though environmental factors can influence the sporadic AD development, genetics 
appears to be the most important risk factor, with over 80% of heritability as shown 
in a large twin-study (Gatz et al., 2006). The most significant genetic risk factor for 
late onset AD (LOAD) is APOE4 allele. As APOE protein is an important cholesterol 
transport molecule in the cerebrospinal fluid (CSF), it has been suggested that APOE 
may influence the pathogenesis by affecting the cholesterol transport to the brain. 
Some studies indicate that high plasma/serum cholesterol levels increase risk of 
developing AD (Pappolla et al., 2003; Popp et al., 2013). Others suggest that it is an 
increase in the low- density lipoprotein cholesterol (LDL-C) specifically that 
contributes to the diseases risk (Kuo et al., 1998). Interestingly, recent findings 
show that that APOE interacts with LDL receptor (LDLR) in an isoform specific 
manner, affecting regional brain APOE protein and cholesterol levels and thus 
influencing cognitive function (Johnson et al., 2014). Although APOE4 allele 
accounts for most of the genetic risk of sporadic AD, other genes may also play a 
role; however, no single one has been verified with certainty (Blomqvist et al., 
2006). Recently, numerous genome-wide association studies have shown an 
association of different SNPs within TOMM40 gene and LOAD (Grupe et al., 2007; 
Feulner et al., 2010; Carrasquillo et al., 2009; Harold et al., 2009). As sporadic AD is 
a complex heterogeneous disease, the susceptibility genes may act in combination 
together with environmental risk factors and contribution of each of them in the 
diseases risk may be minor. 
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1.2 Alzheimer’s disease clinical features and pathogenesis  
AD is a progressive neurodegenerative disease that usually starts slowly, impairing 
the episodic memory at first and affecting language, orientation, behaviour, mood 
and motivation as the disease progresses. The neurodegeneration in AD may start 
up to 20-30 years before the diseases onset (Davies et al., 1988) and is caused by 
deposition and toxic activity of extracellular amyloid Beta (Aβ) and abnormally 
phosphorylated tau protein inside of the neurons. At certain point the threshold is 
exceeded and the first symptoms start occurring. The first clinical phase of AD is 
often referred as mild cognitive impairment (MCI), which is characterised by 
memory loss. MCI can be either a sign of early AD, or could be a benign symptom 
associated with normal ageing.  
The specific mechanisms of the disease pathology are not fully understood. As our 
knowledge of AD increases, so does the awareness of the complex nature of its 
pathogenesis.  
Amyloid plaque counts positively correlate with the disease’s severity, which 
indicates their importance in the AD pathology. Aβ is obtained from amyloid 
precursor protein (APP) in a multi-step proteolytic  process involving β- and γ-
secretases. As Aβ is produced during normal cell metabolism, it has been 
hypothesised that it is the imbalance between the Aβ synthesis and clearance, that 
initiates the pathological process of neurodegeneration eventually leading to 
dementia. Mutations in the key enzymes (PSEN1 and PSEN2) as well as the 
substrate (APP), necessary for Aβ synthesis, present in the FAD, provide support for 
this hypothesis. Moreover, people with Down syndrome have an extra copy of APP 
gene and they develop amyloid plaques earlier in life, which reinforces the 
hypothesis that APP overexpression initiates Aβ deposition and aggregation. 
Although, at first, only the plaque-forming large insoluble fibrils were thought to be 
neurotoxic, some research indicates that soluble oligomers may contribute to 
inhibited hippocampal long-term potentiation and disrupted synaptic plasticity 
(Walsh and Selkoe, 2004).  
Neurofibrillary tangles are composed of abnormally phosphorylated tau protein. 
Normal tau is important for microtubule assembly and stability. However, when the 
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balance between kinases, such as GSK-3β and CDK5 and phosphatases, such as PP-1 
and PP-2A which are responsible for tau phosphorylation becomes disrupted, it can 
lead to intracellular tau hyperphosphorylation and normal tau sequestration (Iqbal 
et al., 2005). As a result of tau sequestration, microtubules become unstable and 
may disassemble, leading to impaired axonal transport and subsequently 
compromised neuronal and synaptic function (Iqbal et al., 2005). Insoluble tau 
fibrils aggregating in the tangles further compromise neuronal function. It is not 
clear whether hyperphosphorylation of tau and formation of tangles is a cause or a 
result of AD. 
There are some studies demonstrating comorbidity of cerebrovascular disease and 
AD pathology (Cruchaga et al., 2013; Mayeux, 2003; Farkas and Luiten, 2001), which 
suggest they may be an overlap between the cerebrovascular pathology and 
amyloid plaque formation. Dysfunctional blood vessels may aggravate cognitive 
impairment by reducing transport of nutrients to neurons and Aβ clearance 
(Iadecola, 2004). Cerebrovascular pathology associated with ischaemia, leads to 
APP overexpression and subsequent Aβ deposition (Jendroska et al., 1995; Riekse et 
al., 2004; Sadowski et al., 2004). However, some researchers claim that 
cerebrovascular pathology acts independently of AD pathology, leading to earlier 
onset in patients with otherwise asymptomatic low-grade pathology (Snowdon et 
al., 1997; Riekse et al., 2004). 
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1.3 Apolipoprotein E structure and function 
Apolipoproteins are a group of proteins that have an important role in the lipid 
transport in the plasma as well as in the central nervous system: through binding to 
hydrophobic phospholipids, cholesterol and triglycerides, they promote they 
aqueous solubility. Apolipoprotein E (APOE) is the most extensively studied of the 
apolipoproteins, as it appears to perform multiple functions in the human body. It is 
a key component of the chylomicrons, very low density lipoprotein (VLDL) and high 
density lipoprotein (HDL) synthesised predominantly in the liver and the adipose 
tissue (Mahley et al., 1984). In the nervous system APOE is synthesised 
predominantly by non-neuronal cell types, mainly astroglia and microglia, whereas 
the receptors for APOE are expressed by neurons (Zhang et al., 2013). The primary 
functions of APOE include transport and metabolism of cholesterol, other fatty 
acids and fat-soluble vitamins.  
APOE is highly expressed in the brain as it an important lipid transport protein in 
the CSF. Upon peripheral nerve injury, it is produced in the large amounts to aid 
tissue repair by delivering lipids to recovering axons and to Schwann cells during 
remyelination (Huang and Mahley, 2014). APOE lipidation and metabolism are 
regulated predominantly by ATP-binding cassette A1 (ABCA1) cholesterol 
transporter, APOE receptors and APOE proteases (Liao et al., 2017). Lipoprotein 
receptor-related protein 1 (LRP1) and LDLR are the key metabolic receptors for 
APOE (Kim et al., 2009); however, recent finding suggest that APOE may also bind 
to a microglial receptor TREM2 influencing TREM2-mediated microglial 
phagocytosis (Yeh et al., 2016).  
APOE polypeptide consists of 299 amino acids and APOE4 differs from wildtype 
APOE3 by a single amino acid at position 112 (Cys112- Arg) (Rall et al., 1982). 
Changes in the amino acid sequence in APOE4 isoform can lead to structural 
modification and partial unfolding of the globule. Although, the partially folded 
protein was shown to have higher affinity of binding to lipid particles (e.g. 
membranes, lipoproteins) (Morrow et al., 2002; Weers et al., 2001), it tends to be 
more unstable and therefore susceptible to degradation by proteolysis (Hatters et 
al., 2006). 
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1.4 APOE gene and allele distribution 
APOE gene is located on the long arm of chromosome 19 (q13.2) and is 3.7 kilo 
base pairs (kb) long. It has been shown to be highly conserved (~70% homology) 
within other mammalian species including rat, rabbit and canine (McLean et al., 
1983), indicating its high importance. Variants of the APOE gene E2, E3 and E4 are 
the result of the two missense single nucleotide polymorphisms (SNPs) rs429358 (T-
>C) and rs7412 (C->T), leading to amino acid changes (Cys -> Arg) at residues 112 
and 158.  
The allele frequencies vary between population and APOE4 allele frequency tends 
to increase with latitude (Eisenberg et al., 2010). The most frequent genotype 
within human species is APOE3, especially within long-established agricultural 
economy populations, such as Mediterranean basin (85-89%) or East Asian 
population (82-87%) (Corbo and Scacchi, 1999), (G. Davies et al., 2014) indicating an 
advantage of the APOE3 metabolic properties in a transition from the food 
collection to food production. Amongst the population where the food availability 
had been scarce until recently (e.g. aborigines of Australia or Lapps) the most 
common allele is APOE4. As the APOE4 allele is associated with higher cholesterol 
absorption from the intestines as well as higher plasma cholesterol levels, carrying 
this allele may be beneficial under these circumstances (Corbo and Scacchi, 1999). 
It has been suggested that APOE2 isoform does not provide an advantage in any 
particular environmental conditions, as its distribution does not seem to exhibit any 
pattern amid different population (Corbo and Scacchi, 1999).  
 
1.5 APOE role in AD pathogenesis 
APOE can influence AD pathogenesis via a number of mechanisms. Recent studies 
indicate, that increased lipidation of the APOE, which is modulated by upregulation 
of ABCA1 by transcriptional and post-transcriptional mechanisms, inhibits Aβ 
deposition (Liao et al., 2017). Moreover, there are a number of pathways by which 
APOE facilitates Aβ clearance, such as enzymatic degradation, receptor-mediated 
blood-brain barrier (BBB) transport, and Aβ endocytosis by glial cells (Liao et al., 
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2017). In addition to affecting Aβ deposition and clearance APOE may contribute to 
AD pathogenesis by affecting vascular function, neuroinflammation, metabolism, 
synaptic plasticity and transcriptional regulation (Liao et al., 2017). 
A number of studies has previously investigated the levels of APOE mRNA or 
protein in the AD brain and the results are mixed. By most accounts, APOE protein 
levels were decreased in AD brains especially in the hippocampus and the frontal 
cortex regions and the effect was APOE4 dependant. For instance, according to ( 
Bertrand et al., 1995; Beffert et al., 1999) the APOE protein levels were lower in the 
hippocampus and frontal cortex of the AD tissue, which was also associated with 
increased Aβ levels (Beffert et al., 1999). Other studies shown significantly higher 
APOE mRNA in AD brains compared to controls (Lambert et al., 1997; Yamagata et 
al., 2001; Matsui et al., 2007). A study by Mise et al. (2017) investigated APOE 
expression in the peripheral blood and they did not find any significant differences 
in the APOE mRNA levels between AD and controls. 
 
1.6 APOE alleles as AD risk factor 
Carrying at least one APOE4 allele is the strongest known risk factor for late-onset 
AD, whereas the APOE3 variant is believed to be neutral in the disease’s risk, and 
the APOE2 isoform may have protective properties. It has been estimated that 40% 
of all AD patients carry at least one ε4 allele, while homozygosity for APOE4 allele 
increases the risk of AD from 20 to 90% as well as significantly decreasing the age of 
its onset (Corder et al., 1993). The ε4 allele effect on the AD risk is the greatest in 
the 60-70 year olds (Blacker et al., 1997). APOE4 allele has been previously 
associated with decreased APOE protein expression in mouse (Riddell et al., 2008; 
Bray et al., 2004) and human brains (Bray et al., 2004). Interestingly, the mRNA 
expression was not significantly different between the 3 genotypes, suggesting that 
the mechanism that alters protein level is post-translational (Riddell et al., 2008). 
Levels of cholesterol secreted from the astrocytes was also lower in the carriers od 
APOE4 allele. Furthermore, the decreases in brain APOE protein levels were also 
associated with increased risk of developing AD, suggesting that the APOE4 allele 
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may contribute to the AD risk by directly causing the APOE protein deficiency and 
thus impaired synaptic repair and Aβ clearance (Riddell et al., 2008).  
Decades of research have highlighted a number of functional differences among the 
three APOE isoforms, demonstrating their role in the AD pathology. The 
contribution of the APOE 4 isoform to the AD pathology can be divided into the Aβ 
dependent and that independent of the Aβ production. Numerous studies have 
investigated these mechanisms both in vitro and in vivo on the animal models as 
well as on the post mortem samples of the AD patients.  
 
1.7 Aβ dependent mechanisms of the APOE isoforms on the AD 
pathology 
The Aβ dependent pathways have been relatively well-studied as the Aβ deposition 
is the hallmark of the AD pathology. Different APOE isoforms can differentially 
affect the Aβ metabolism and thus aggravate the neuropathology and cognitive 
decline. Under certain conditions, APOE4 binds to and enhances the accumulation 
of Aβ. For instance, it has been shown that in vitro APOE3 and APOE4 that are 
unbound to lipids can form stable complexes with Aβ peptides rendering them 
resistant to degradation by dodecyl sulphate and guanidine hydrochloride and that 
formation of these complexes is faster and more efficient in case of the APOE4 
isoform (Strittmatter et al., 1994; Cho et al., 2001). An in vitro study on transfected 
HEK cells, suggested that APOE3 binds to Aβ with higher affinity than APOE4 and 
therefore enhance clearance, preventing plaque deposition. However, the 
relevance of these results in the AD pathology should be further investigated, due 
to the differences of the APOE secreted by HEK cells and that in the CSF and the 
brain. Although, it has been also suggested that the interaction of APOE and soluble 
Aβ (sAβ) in physiological conditions is minimal and that the APOE influences sAβ 
metabolism not through direct binding, but other mechanisms, such as competition 
of sAβ and APOE molecules for the LRP1-dependent cellular uptake pathway in 
astrocytes. Furthermore, zinc- and copper-induced aggregation of the Aβ is 
increased in the presence of the APOE4 (Moir et al., 1999). Moreover, according to 
(Castellano et al., 2011; Deane et al., 2008), APOE4 reduces the rate of Aβ clearance 
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in mice. Another study, conducted on APOE-deficient mice that expressed APP-
V717F, demonstrated that APOE is actually necessary for  the amyloid plaque 
formation in mice (Bales et al., 1999). Similarly, (Kim et al., 2011; Bien-Ly et al., 
2012) suggested that reduction of the APOE expression can lead to reduction of the 
Aβ levels and thus the rate of the plaque formation, as increasing the expression of 
the APOE3 and APOE4 in the hAPP or hAPP/PS1 transgenic mice, lead to increased 
accumulation of the amyloid plaques. 
Numerous studies investigated effects of the APOE isoforms on the Aβ metabolism 
in the transgenic mice. Overall, the results indicate that mouse APOE enhances the 
Aβ accumulation (Bales et al., 1999), whereas human APOE, in the absence of 
mouse APOE, reduces the plaques deposition (Holtzman et al., 2000) and that 
APOE2 and APOE3 are more efficient at Aβ clearance than APOE4 (Holtzman et al., 
2000; Dodart et al., 2005). One of the studies on the hAPP-V717I transgenic mice 
found that APOE4 expressed by neurons, unlike the one expressed by the glial cells, 
enhanced the amyloid plaque formation in the hippocampus and cortex (Van 
Dooren et al., 2006). Although, in a different study, increased APOE4 expression in 
the astroglia and neurons did not have an effect on the Aβ levels (Lesuisse et al., 
2001). One of the suggested mechanisms of the APOE role in the Aβ clearance is 
astrocyte-mediated degradation and (Koistinaho et al., 2004) suggested that 
different APOE isoforms differentially regulate astrocyte colocalisation and 
therefore modify their ability to clear the Aβ peptides. 
Even though the majority of research suggests that APOE isoforms influence AD 
pathology mainly through regulation of the plaque formation, other studies 
indicate that there are mechanisms that are independent of the plaque formation 
(Buttini et al., 2002; Raber et al., 2000).  
 
1.8 Aβ-independent effects of the APOE isoforms on the AD pathology  
Although, APOE4 has a number of implications in the Aβ accumulation and toxic 
activity, it also has a role in the AD pathology independently of the Aβ. For instance, 
transgenic mice, which were induced to express human APOE4, instead of the 
endogenous mouse APOE, performed significantly worse in the cognitive testing 
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(water maze and the vertical exploratory behaviour) than the mice that were 
expressing human APOE3 or the wild type (Buttini et al., 1999; Raber et al., 1998). 
This effect was especially pronounced in the female mice, suggesting that the 
APOE4 effect could be gender-dependent. Morphology assessments of these 
transgenic mice, suggested that APOE3, but not APOE4 was protective against 
kainic acid-induced neurodegeneration that was apparent in the APOE knockout 
mice. Other studies have also suggested that APOE4 is linked to impaired memory 
and spatial learning in the transgenic mice (Andrews-Zwilling et al., 2010; Leung et 
al., 2012; Hartman et al., 2001). As there is no Aβ accumulation in these transgenic 
mouse models, these findings support the Aβ-independent role of APOE4 in the 
neurodegeneration. There are a few suggested mechanisms of the APOE protein 
fragments neurotoxicity. Examples of these would include induction of the Tau 
phosphorylation, cytoskeleton disruption and mitochondrial dysfunction. According 
to Chang et al. (2005), APOE4 is able to enter the cytoplasm by translocation 
facilitated by positively charged receptor-binding region, allowing the lipid-binding 
region to interfere with the mitochondria. APOE genotypes associate with the 
mitochondrial dysfunction, with APOE4 carriers being more affected than APOE3 
carriers (Gibson et al., 2000). APOE4 carriers (both AD and controls) have reduced 
glucose metabolism in the brain (Drzezga et al., 2005; Hirono et al., 2002; Mosconi 
et al., 2005). This implies that APOE4 can have an effect on the AD development via 
dysregulation of mitochondrial function in the very early phases of the disease 
pathogenesis. 
 
APOE3, unlike APOE4 binds to unphosphorylated tau, possibly preventing its 
phosphorylation (Strittmatter et al., 1994). Transgenic mice expressing human 
APOE4 had significantly higher tau phosphorylation that was specific to neurons 
(Brecht et al., 2004; Tesseur et al., 2000a; Tesseur et al., 2000b). By inducing tau 
phosphorylation, APOE can induce formation of neurofibrillary tangles and thus 
contribute to AD pathogenesis. Interestingly, removing tau protein, reduced the 
neurotoxic effect of the APOE4 in the transgenic mice (Andrews-Zwilling et al., 
2010). In a large GWAS study on the AD patients and controls, APOE4 allele was 
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associated with increased tau phosphorylation in CSF irrespectively of the Aβ levels 
(Cruchaga et al., 2013).  
 
As mentioned previously, APOE4 isoform is more sensitive to proteolysis than the 
APOE3 isoform and fragments produced by the degradation can impair the repair 
and remodelling leading to neurodegeneration (Huang, 2010); (Huang and Mahley, 
2014). Significantly higher levels of the carboxyl-terminal-truncated APOE4 have 
been found in the Alzheimer’s brains compared to controls and the levels were 
even higher in the carriers of two APOE4 alleles (P. B. Jones et al., 2011; Huang et 
al., 2001; Harris et al., 2003). The fragmented APOE4 were also deposited in the 
neurofibrillary tangles and amyloid plaques of the AD brains (P. B. Jones et al., 
2011; Huang et al., 2001). In vitro, the APOE fragments that were expressed by the 
cells or added to the culture, stimulated the neurofibrillary tangle-like inclusions 
and thus were neurotoxic (Huang et al., 2001; Ljungberg et al., 2002).  
 
APOE4 isoform also may also contribute to AD pathology by negatively affecting 
neuronal plasticity and neurite extension. In vitro, APOE4 was linked to neurite 
branching restriction and cytoskeleton disruption (Holtzman et al., 1995; Nathan et 
al., 1994). Similarly, in transgenic mouse models, APOE4 expression was related to 
disrupted cytoskeletal stability due to interference with microtubule formation and 
decreased β-tubulin polymerisation (Tesseur et al., 2000a). Whereas APOE3, 
expressed by the mouse hippocampal neurons, enhanced neurite outgrowth (Sun 
et al., 1998). Furthermore, in the cell cultures, APOE3 was more efficient at 
enhancing neurite extension than the APOE4 isoform. It has been suggested that 
APOE mediates neurite outgrowth via Erk pathway activation, which has been 
demonstrated in primary neuronal cell cultures. 
APOE isoforms have also been shown to affect integrity of the BBB in mouse 
models (Bell et al., 2012). Specifically, APOE4 increased the risk of the BBB damage 
due to activation of the inflammatory pathways. 
 
Studies on transgenic mouse models demonstrated that APOE4 can be associated 
with hilar GABAergic neurons impairment and thus reduction in the hippocampal 
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neurogenesis, resulting in learning and memory difficulties. The role of APOE4 on 
the GABAergic mediated cognitive impairment have been also studied in humans. 
AD is associated with reduced GABA and somatostatin levels in the brain and CSF 
(Bareggi et al., 1982; P. Davies et al., 1980; Hardy et al., 1987; Seidl et al., 2001; 
Zimmer et al., 1984) and this is more pronounced in the patients carrying at least 
one APOE4 allele (Grouselle et al., 1998). Reduction of GABA levels with age is the 
strongest known AD risk factor. Therefore these findings support the role of APOE4 
isoform in the AD pathology via GABA regulation. 
 
Despite all of the research conducted both in vitro and in vivo on animal models as 
well as human post mortem brains, the specific mechanisms through which 
different APOE alleles modify AD risk, remain incompletely understood. Moreover, 
carrying the APOE4 allele alone is not enough to develop AD, nor is it essential for 
the disease development. It has been suggested that APOE alleles might display 
variation in the transcriptional regulation affecting the gene expression and 
therefore influencing the AD pathology. 
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1.9 TOMM40 gene in AD 
TOMM40 gene is located on the long arm of the chromosome 19 (q13.32) closely 
adjacent to the APOE gene. It is 13.12 kb long and encodes for translocase of outer 
mitochondrial membrane 40 (TOMM40) protein. TOMM40 is a polymorphic gene 
and numerous studies have investigated its role in the AD pathology.  
Some polymorphisms in the TOMM40 gene have been implicated as a potential risk 
factor in AD (X. Y. Ma et al., 2013), especially TOMM40’523 polyT length 
polymorphism, which has shown an association with the age of onset of AD (Roses 
et al., 2010; Roses et al., 2016). However, Mise et al. (2017) findings suggest that 
the TOMM40’523 polyT genotypes were not significantly different between AD and 
controls. 
According to Mise et al. (2017), TOMM40 mRNA expression is significantly lower in 
the peripheral blood of the AD patients compared to controls and correlates with 
cognitive decline, which was measured using Mini-Mental State examination test. 
Overexpression of TOMM40 mRNA has been suggested to be protective against 
mitochondrial dysfunction (by protecting against some mitotoxic effects of 
intracellular Aβ peptide) and thus neuronal damage (Zeitlow et al., 2017). One 
study presented a hypothesis that mitochondrial dysfunction may be the first 
pathophysiological event in AD and that TOMM40 may have a protective role in this 
process (Ferencz et al., 2012).  
Due to the TOMM40 gene location in the genome, preceding the APOE gene, it is 
thought to be in a linkage disequilibrium with the APOE gene (Yu et al., 2007; Caselli 
et al., 2012). One study suggested that certain TOMM40 SNPs may be in a linkage 
with APOE4 allele and thus strongly associate with late onset AD (LOAD) (Yu et al., 
2007). However, after adjustment for confounders, only the APOE4 association 
remained significant, suggesting that TOMM40 only associates with the AD risk due 
to its linkage disequilibrium with the APOE gene (Yu et al., 2007). Another study 
suggested that certain SNPs within TOMM40 gene, APOE promoter and distal APOE 
enhancers influence CSF APOE protein levels (Bekris et al., 2008). Therefore, it is 
imperative that the whole TOMM40-APOE locus rather than the APOE gene alone is 
investigated in the context of AD pathology. 
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1.10 Gene methylation in AD 
Methylation is a process of adding a methyl group to a DNA sequence by an enzyme 
methyl transferase. It typically occurs at cytosine which is followed by guanine in a 
DNA sequence—a CpG site. A cluster of CpG sites in a given gene region is called a 
CpG island. Gene expression can be affected by methylation levels due to the 
methyl group blocking access for the transcription factors to the important 
regulatory regions. Transcription factor binding can up- or down-regulate gene 
expression, depending on its type. For instance, transcription factors may enhance 
or block binding of the RNA polymerase to DNA; alternatively, they can affect 
histone acetylation by catalysing histone acetyltransferase (HAT) or histone 
deacetylase (HDAC). They can also catalyse the reactions indirectly by facilitating 
binding of the coactivator or corepressor protein to the complex. Promoter and 
enhancer regions methylation would typically have the highest influence on the 
gene expression. In majority of cases, hypermethylation of the promoter or 
enhancer would lead to decreased gene expression (Bae et al., 2016). There are, 
however, cases where highly regulatory regions were associated with enhanced 
expression. For instance, TREM2 (a gene that has been associated with AD) 
promoter hypermethylation is associated with enhanced gene expression (Smith et 
al., 2016).  
Numerous environmental factors such as diseases can affect gene methylation. 
Ageing and age-related diseases associate with methylation levels both in humans 
(Siegmund et al., 2007; Xiao et al., 2015; Peters et al., 2015; Slieker et al., 2016; 
Bollati et al., 2009; Reynolds et al., 2015) and mouse models (Chouliaras et al., 
2012; Maegawa et al., 2010). DNA is differently methylated in AD patients and in 
mouse models (Chouliaras et al., 2012; Coppieters et al., 2014; Sanchez-Mut et al., 
2013), which may indicate that DNA methylation could influence the AD 
pathogenesis. Due to the strong association of ageing and the methylation levels, it 
has been suggested that gene methylation may have crucial role in AD disease 
development as the age of onset is typically over 65 years. 
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1.11 TOMM40-APOE locus methylation in association with AD 
Methylation of the APOE gene has been studied relatively well, especially the 
promoter region, which is hypomethylated as well as the exon 4 CpG island, which, 
on the contrary, is highly methylated (Y. Ma et al., 2015). APOE methylation may be 
influenced by the genotype, especially considering that SNPs responsible for the 
three APOE alleles may either disrupt or create a CpG site. Indeed, there are certain 
studies that show significant association of the APOE methylation levels with the 
genotype (Ma et al., 2015). Furthermore, APOE methylation levels have been 
associated with plasma total cholesterol levels (Ma et al., 2015). 
APOE gene methylation has been previously shown to influence APOE protein level 
and thus correlate with AD pathology. For example Foraker et al. (2015) and Tulloch 
et al. (2018a) found that the APOE gene displayed significantly lower methylation in 
the frontal lobe and the hippocampus of the AD patients compared to the controls. 
Interestingly they found no methylation difference in the cerebellum, which is 
known to be less affected by AD than the two other aforementioned regions 
(Foraker et al., 2015). An exploratory study on the small number of brain (n = 12) 
and blood samples (n = 67) suggested that methylation of the TOMM40-APOE-
APOC2 gene region may associate with AD pathology via regulating TOMM40 and 
APOE expression (Shao et al., 2018). Moreover, they suggested that the 
methylation levels of the locus differed significantly between the blood and brain 
samples (Shao et al., 2018). Similarly, a recent study on Swedish twins found that 
methylation of the APOE promoter region (including the intergenic region between 
TOMM40 and APOE gene) was increased in the AD peripheral blood and that the 
effect was independent of the APOE genotype (Karlsson et al., 2018). As majority of 
previous studies only investigated the effect of the APOE region methylation on AD 
in a small number of samples, it is still not fully understood how methylation of the 
TOMM40-APOE locus in the brain relates to AD neuropathology in a larger number 
of samples characterised for longitudinal cognitive decline. 
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1.12 Aims and objectives. 
1.12.1 Aims 
To investigate whether the TOMM40-APOE locus is differentially methylated in the 
AD brains and whether their methylation level correlates to the APOE protein levels 
in the brain.  
 
1.12.2 Objectives 
1. Investigate a collection of AD and healthy prefrontal cortex samples for levels of 
APOE protein using an ELISA and relate this to AD neuropathology (i.e. Braak stage, 
Thal and CERAD score). 
2. Investigate DNA methylation differences at the APOE exon 4, TOMM40 promoter 
region and the intergenic region, using bisulphite pyrosequencing, and relate to 
APOE alleles and APOE protein levels in the brain.  
3. Investigate the localization of the APOE protein in the prefrontal cortex of AD 
brains compared to the healthy brains using the immunohistochemistry (IHC) 
staining with anti-APOE antibody. 
 
1.13 Hypothesis 
APOE methylation is increased in AD, leading to decreased APOE gene expression 
and thus reduced levels of APOE protein in the brain. The methylation of CpG sites 
in the surrounding regulatory regions TOMM40 gene and the intergenic region also 
influence the APOE protein expression. 
By regulating APOE protein expression, the methylation levels associate with AD 
pathology and cognitive performance.  
The APOE alleles differentially regulate AD pathology partially via affecting 
methylation levels. 
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2. Materials and methods. 
2.1 Study material 
The prefrontal cortex brain samples that were used for the analysis in this study 
were obtained from Manchester Brain Bank. The participants included 46 females 
and 21 males (mean age of death 87.5, SD=6.1) of Caucasian population from 
Manchester. The participants were previously tested for fluid intelligence, 
vocabulary, speed and memory. Both cross-sectional and longitudinal biennial 
cognitive assessment results were included in the analysis. The method of the 
cognitive assessment was previously described (Rabbitt et al., 2004).  
Ethical approval has been granted for the original study where the samples have 
been obtained from and no further ethical approval was necessary for the present 
study. All subjects have provided a written consent to donate their post-mortem 
samples to the brain bank for research purposes.  
Risk assessments and COSHH form have been completed prior to the 
commencement of this study and all of the necessary precautions have been 
undertaken to ensure safety and security in the laboratory environment. 
 
2.2 Brain pathology assessment 
The brain samples were previously assessed and staged by experienced 
pathologists at the brain bank using the ‘ABC score’ recommended by National 
Institute on Aging–Alzheimer’s Association (Hyman et al., 2012), involving 3 scores: 
Thal—Aβ plaque score (Thal et al., 2002) Braak–neurofibrillary tangles stage (Braak 
and Braak, 1991) and CERAD—neuritic plaque score (Mirra et al., 1991). AD and 
controls were defined on the basis of these pathological scores. AD was defined as 
scores of 3 or grater in Braak, B or higher in CERAD and 2 or higher in Thal. 
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2.3 APOE protein quantification  
The protein lysate used for the APOE protein quantification was previously 
extracted from the brain tissue using RIPA buffer (Sigma) and 1x protease inhibitor 
cocktail (Sigma). The procedure has been described previously in detail (Bradburn 
et al., 2018). 
The levels of the APOE protein in the brain were measured using Abcam 
Apolipoprotein E Human ELISA kit according to the manufacturer’s instructions. The 
absorbances at 450 and 570 nm were measured using Synergy HT microplate 
reader. The raw data was then analysed using Microsoft Excel 2016 and Prism 
Graphpad (version 7.0a). To enable estimation of the APOE protein concentration, 7 
standards of known concentrations were included on the plate and their 
concentration vs absorbance were plotted as a hyperbola standard curve using 
Prism Graphpad (version 7.0a). The unknown concentrations of the samples were 
then interpolated onto the curve using the known absorbance. The raw values were 
then standardised for the total protein concentration in each sample.  
 
2.4 DNA extraction 
Genomic DNA was extracted from the prefrontal cortex samples of the brain using 
Bioline Isolate II genomic DNA Kit (Bioline, UK), according to the manufacturer’s 
instructions. The concentration and purity were measured using NanoDrop 2000c 
spectrophotometer (Thermo Scientific, Wilmington, USA). Absorbance ratios at 
260/280 and 260/230 were used as the indicators of the DNA purity, to ensure the 
DNA was free of protein and salt contamination. DNA solutions were stored at -80C 
until further analysis. 
 
2.5 Genotyping 
Genotyping of the APOE rs7412 and rs429358 was done previously and described 
together with the quality control procedures by Davies et al. (2014). Briefly, the two 
APOE SNPs were genotyped using the Sequenom MassARRAY iPLEX platform (G. 
Davies et al., 2014). Table 1 shows how the rs429358 and rs7412 genotypes 
represent E2/E3/E4 alleles. 
 24 
 
Table 1 Genotypes associated with APOE alleles 
Alleles Rs429358 genotype Rs7412 genotype 
E2/E2 TT TT 
E2/E3 TT TC 
E2/E4 TC TC 
E3/E3 TT CC 
E3/E4 TC CC 
E4/E4 CC CC 
 
2.6 Methylation analysis 
2.6.1 Bisulphite treatment 
The DNA samples (250 ng) were bisulphite converted with the use of Qiagen 
EpiTect Fast DNA Bisulphite Kit (Qiagen, Hilden, Germany). Prior to the conversion, 
the DNA samples were diluted to achieve an equal concentration of 12.5 ng/μL. The 
samples were then mixed with bisulphite solution and DNA protect buffer and 
incubated in the Eppendorf Mastercycler thermal cycler, using thermal conditions 
specified by the kit’s manufacturer (shown in Table 2). The converted DNA was then 
treated with DNA binding buffer and placed in the spin columns to perform wash 
steps for desulphonation and purification. A volume of 30 μL was eluted (2 x 15μL) 
and stored at -20° C until amplification.  
Table 2 Bisulphite conversion thermal cycle conditions. 
Step Description Time Temperature [℃] 
1 Denaturation 5 minutes 95 
2 Incubation 10 minutes 60 
3 Denaturation 5 minutes 95 
4 Incubation 10 minutes 60 
5 Hold indefinite 20 
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2.6.2 Target regions analysed and primers used 
 
Figure 1 Genomic map of TOMM40- APOE locus showing approximate locations of the CpG sites investigated 
in this study. Black bars represent CpG islands. Grey bars represent gene exons. Transcription of the genes 
occurs from left to right as shown by arrows. Schematic representation - the scale only approximately represents 
the length of genes.  
 
The three regions of interest, TOMM40 promoter region, APOE exon 4 and the 
intergenic region were identified using previous publications (Shao et al., 2018; 
Foraker et al., 2015) and Genome browser (University of California Santa Cruz) was 
used to get their sequences. Figure 1 show the approximate location of the 
investigated CpGs in the TOMM40-APOE locus. The primers that were used for DNA 
amplification and pyrosequencing were designed using Pyromark Assay Design SW 
2.0 (Qiagen, Hilden, Germany) and manufactured by Invitrogen by Thermo Fisher 
Scientific. The forward, reverse and sequencing primers and the sequence analysed 
for each region are shown in table 3. 
 
Table 3 Sequences in TOMM40 promoter APOE exon 4 and the intergenic region analysed in this study and 
primers used for their amplification and sequencing 
Gene location Primers; Forward, reverse, sequencing  
* Biotin tagged 
Sequence analysed (CpGs numbered) 5’-3’ 
APOE exon 4 F: ATGAAGGAGTTGAAGGTTTATAAAT 
R: AACCCCCACCTAATACACTACCAA * 
S1: GGGTAAGGTTGTTTAAGGA 
S2: GGGTGAGTTTAGTTTTTTATTTG 
1.GTTGTAGGYGGYGTAGGTTYGGTTGGGYGYGGATATGGAG
GAYGTGYGYGGTYGTTTGGTGTAGTATYGYGGYGAG 
2. YGTAAGTTGY GTAAGYGGTT TTTTYGYGAT GTYGATGATT 
TGTAGAAGYG TTTGGTAGTG TATTAGGTYG 
TOMM40 F: GTTTTAGGGTAGAAGGATAGGTAAAGG 
R: AACACTCTAAAAAAAACCAACACTT * 
S: TTTGGTTAGGAGTAGT 
YGATTTAAAA TYGGAAGTGT TGGTTTTTTT TAGAGTGTTT 
Intergenic 
region 
F: TTGGGATTTATAATAGGGTTTAGGAAAGTG 
R: CCTCTCTAAACATCAAATTCCTTTACT * 
S: AGGGTTTAGGAAAGTGATA 
 
GYGTTTGAGY GTTTATTGTG GTTTGTTTAT TGTTAGTTTT 
AATATAGGAT YGTTGTGTGT TAGGGTTGTT TTTTATGTTT 
AATATAYGTT AGTTTGTTAT TAAATATATT YGTGTYGTTG 
TTTTTTTAGT TTGATGAGTA AAGGAATTTG ATGTTTAGAG 
AGGATAAGTT ATTTGTTTAA GGTTATATAG TTGGTAATTG 
GTAGAGTTAG 
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2.6.3 Polymerase chain reaction (PCR) 
A hot start PCR was performed using the forward and reverse primers shown in 
table 4. The master mix was prepared using 12.5 μL MyTaq HS (Bioline), which 
contains DNA polymerase, dNTPs, MgCL2 and enhancers, 0.5 μL forward primer, 0.5 
μL reverse primer, 2.5 μL coral load dye and 7 μL molecular grade water. The 
reactions containing 2 μL of the bisulphite converted template DNA and 23 μL of 
the master mix were set up in the sterile 200 μL PCR tubes, spun down using a 
centrifuge and amplified using Eppendorf Mastercycler thermal cycler. All of the 
preparations were carried out on ice to avoid unspecific binding and the 
preparation of the master mix was conducted under a PCR hood to avoid foreign 
DNA contamination. Initially, the thermal cycling conditions recommended by the 
MyTaq manufacturer were used. However, the gel electrophoresis and 
pyrosequencing results shown that these conditions were not satisfactory. 
Therefore, the primer annealing temperatures were optimized using a gradient. 
Ultimately, the annealing temperature of 58°C was used for all of the amplification 
of all three regions (see results). 
Table 4 DNA amplification PCR thermal cycling conditions 
Step Description Temperature (°C) Time 
Number of cycles per 
step 
1 
Hot Start (DNA 
Polymerase activation) 
95 5 minutes 1 cycle 
2 
Denaturation 95 30 seconds 
50 cycles Annealing 56 30 seconds 
Extension 72 30 seconds 
3 Hold 4 indefinite 1 cycle 
 
2.6.4 Agarose gel electrophoresis 
Gels were made using 2% of agarose mixed with 1 x tris-borate-EDTA (TBE) buffer 
and Midori Green Advance DNA stain (NIPPON Genetics Europe) in the proportion 
of 5 μL of stain per 100 ml of gel. The PCR products and 50 bp DNA hyperladder 
(Bioline) were loaded onto the gel and electrophoresed in the tanks containing 1x 
TBE buffer at 90 V for 30-60 minutes. Coral load dye was added to the PCR 
reactions prior to their amplification. The gel images were acquired using Odyssey® 
Fc imaging system (LI-COR Biotechnology, UK). 
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2.6.5 Bisulphite pyrosequencing  
DNA methylation analysis of the APOE, TOMM40 and the intergenic region was 
carried out using the bisulphite pyrosequencing method on the Pyromark Q24 
system (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. The 
sequencing master mix contained Streptavidin Sepharose High Performance beads 
(GE Healthcare Biosciences), Pyromark binding buffer and molecular grade water in 
the ratio of 1:40:19 respectively. 60 μL of the master mix was combined with 20 μL 
of the PCR product on the 24-well plate and shaken at 1400 RPM for 10 minutes at 
room temperature using the TS-100 thermo-shaker (BioSan). Samples were then 
placed on to the Pyromark workstation and processed with the vacuum filtered 
probes for 15 seconds to ensure all of the liquid was aspirated and the beads 
containing the DNA template were captured in the probe’s filter. The probe was 
then flushed for 5 seconds in 70% ethanol, 5 seconds in denaturation buffer and 10 
seconds in wash buffer to ensure all the DNA fragments that were unbound to the 
beads were washed away. The probe was subsequently placed onto the 24-well 
sequencing plate containing the sequencing primers diluted to 0.3 µM 
concentration with Pyromark annealing buffer, ensuring the vacuum was switched 
off, and shaken to enable the beads to be released into the wells. The samples were 
then incubated at 80° C for 2 minutes on a heating block (DB-2D, Dri-Block®, 
Techne). The sequencing plate was then placed in the Pyromark Q24 sequencer 
together with a cartridge containing enzyme mix, substrate mix and the deoxy 
nucleotide triphosphates (dNTPs) in the proportions according to the pre run 
information for the specific run on the PyroMark Q24 Advanced software.  
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2.7 Immunohistochemistry staining 
The prefrontal cortex samples (3 control and 3 AD) were cut into sections using the 
cryostat at -18° C and stored at -80° C until the analysis. The slides were air dried 
after thawing, re-hydrated with 0.05% PBS-T for 10 minutes and then blocked for 
30 minutes with 4% goat serum in PBS-T to prevent unspecific binding. The sections 
were then incubated for 24 hrs at room temperature with rabbit APOE polyclonal 
antibody (ProSci, Poway, USA) at concentration of 20 μg/mL and NovocastraTM Glial 
Fibrillary Acidic Protein (GFAP) mouse monoclonal antibody (Leica Biosystems, 
Newcastle, UK) at concentration 0.14 ug/mL (both concentrations recommended by 
the manufacturers for the purpose) diluted in the blocking buffer (4% goat serum). 
Following incubation the slides were rinsed with PBS-T for 5 minutes and incubated 
for 30 minutes with two secondary antibodies Alexa Fluor 488 goat anti-rabbit IgG 
and Alexa Fluor 568 goat anti-mouse IgG, both diluted 1 in 200 in blocking buffer. 
The slides were subsequently mounted using Vectashield antifade mounting 
medium with DAPI (Vector Laboratories, Peterborough, UK) and coverslipped. The 
slides were then wrapped in aluminium foil to avoid fading due to light exposure 
and stored at 4° C. The stained slides were then viewed and photographed under 
fluorescent microscope at magnification x200 and x630. 
 
2.8 Statistical analysis 
All statistical analyses were performed in the SPSS statistics (version 25, IBM 
statistics). The significance threshold was accepted at p<0.05. In case of the Hardy- 
Weinberg equilibrium, the P> 0.01 was accepted due to the small sample size and 
low minor allele frequency. The continuous data was tested for normal distribution 
using Kolmogorov- Smirnoff test. Data are presented as mean ±  standard deviation 
(SD) if normally distributed or median and 25th- 75th percentiles if not normally 
distributed, if otherwise stated. Square root transformation was performed on 
APOE protein levels data and arcsine transformation on some of the CpG 
methylation data to achieve normality. Continuous Pearson’s Chi-squared goodness 
of fit test was used to determine if the alleles were in Hardy-Weinberg equilibrium. 
Continuous data were tested using t-test to determine differences between AD and 
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controls. Chi-square tests were performed to determine distribution differences 
between nominal data. T- test (or a Mann Witney-U test for not normally 
distributed data) was used to determine differences in APOE protein levels and 
methylation levels between the genders. The methylation levels as well as the 
protein level were also tested using two-way ANOVA to determine possible 
genotype (APOE4 carriers vs non APOE4 carriers) and disease (AD vs controls) 
effects as well as disease x genotype interactions. To determine differences in the 
cognitive test between AD and controls, Mann-Whitney U test was performed. 
Spearman correlation test was performed to determine association of the ApoE 
protein level and the methylation status with the AD pathology scores (Thal staging 
for amyloid deposition, Braak staging for neurofibrillary tangles and CERAD staging 
for neuritic plaques). To adjust for confounding factors, ordinal regression model 
was performed on factors that associated significantly. Pathology stages were set as 
dependent variable and APOE protein level as well as gene methylation were set as 
independent variables together with other potential confounders including age at 
death and APOE4 allele, as both of these could have an effect on the brain 
pathology. To determine association of APOE protein level and methylation status 
with cognitive measures, Pearson correlation was performed initially, followed by 
linear regression. Cognitive measure was set as dependent variable and APOE 
protein level, methylation status, gender, age at cognitive testing and APOE4 
presence were set as independent variables to determine, whether the correlation 
remained significant after adjustment for confounding factors. 
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3. Results 
3.1 PCR optimization 
To improve the efficiency of the bisulphite pyrosequencing, the PCR reactions 
needed to be optimised to ensure sufficient yield and avoid unspecific binding, 
which could influence quality of the product. The quality and yield of the PCR 
product was tested using agarose gel electrophoresis. Initially, when the thermal 
conditions recommended by the manufacturer of the master mix were used, the 
bands on the gel image were faint, suggesting low concentration of the product. 
When the PCR product was tested on the pyrosequencer, the signal was very low 
and the sequencing failed. Firstly, the reactions were optimized by increasing the 
annealing temperature from the initial 56° C to 58° C. Figure 2 shows the PCR 
performed with a gradient of annealing temperatures 55 +/- 3° C. In case of 
TOMM40 and the intergenic region, the annealing temperature of 58° C was 
optimal and produced enough high-quality product, which then could be used for 
bisulphite sequencing. However, in case of the APOE region, the annealing 
temperature adjustment on its own did not give sufficient yield to produce high 
enough signal on the pyrosequencer. Therefore, both forward and reverse primers 
were redesigned and tested in different combinations. The new sets of primers 
were tested for different annealing temperatures, to determine which will result in 
optimal quality and yield of the product. The results gel image is shown in figure 3 
and 4. The optimal annealing temperature that was used for the three regions was 
found to be 58° C. TOMM40 and the intergenic region PCR did not require any 
further optimization.  
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Figure 2 PCR optimization for the APOE exon 4 DNA region using the annealing temperature gradient starting at 
55°C +/- 3°C. (The image was cropped to remove bands from another analysis that was not relevant to this 
study) 
 
 
Figure 3 Gel image showing results of a PCR using two  different APOE primer combinations at a  gradient 
starting at 57°C +/- 3°C. Lanes 9 and 17 show the negatives. Ultimately second primer combination at annealing 
temperature of 58°C was used. 
 
APOE primer set 1 APOE Primer set 2 
54C      55C      56C      57C      58C       59C     60C   57C (N) 54C      55C      56C      57C      58C       59C      60C    57C (N) 
300 bp 
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3.2 Pyrosequencing assay optimization and troubleshooting 
The major issue with the pyrosequencing method that was encountered, was the 
signal strength. The first line of troubleshooting was PCR optimization discussed in 
the previous paragraph. When the maximum yield of the PCR product was 
achieved, and the sequencing signal was still insufficient, the volume of the PCR 
product added to the sequencing reaction was increased from 10 μL to 20 μL and 
the volume of water was reduced accordingly to ensure the concentration of other 
reagents remained constant. In case of the TOMM40 and the intergenic region, 
sequences (which were relatively short), increasing the amount of PCR product 
added to the reaction resolved the problem of low signal strength and did not need 
to be further optimised. In case of the APOE region with a significantly longer 
sequence used initially, the sequencing primers were re-designed and two shorter 
sequences were analysed separately. This greatly increased the signal strength. 
However, the volume of the PCR product added to the sequencing reaction needed 
to be further increased to 25 μL. Despite all these steps being undertaken, a 
number of samples did not give satisfying results for the APOE region methylation, 
specifically 21% of the samples for the sequencing primer 1 and 13% for the 
sequencing primer 2. Due to the time constrains of the project, the assays could not 
be further optimised and only the results that were of acceptable quality were 
included in the analysis. 
 
3.3 APOE Genotypes 
Genotypes of all of the 67 is show in table 5 (G. Davies et al., 2014). The Chi-
squared goodness of fit analysis revealed that both rs429358 and rs7412 alleles 
were in Hardy Weinberg equilibrium (p = 0.988 and p=0.034 respectively).  
Table 5 Genotype frequencies of APOE rs429358 and rs7412. 
 Genotype frequency [n(%)] 
SNP CC CT TT 
Rs429358 2 (3.0) 20 (29.8) 45 (67.2) 
Rs7412 57 (85.1) 8 (11.9) 2 (3.0) 
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3.4 Cohort characteristics 
Table 6 shows the participants characteristics stratified by disease status. Although 
all of the samples have had the pathological assessments performed at the centre 
(including Thal, Braak and CERAD), it was difficult to clearly assign some of the 
samples to AD or control group, due to discrepancies between different scoring 
systems, which led to difficulty in distinguishing between age changes and early 
signs of AD. Moreover, some of the samples would display pathology characteristic 
for diseases such as dementia with Lewy bodies (DLB) or cerebrovascular disease 
together with AD pathology, which could have affected the results. Therefore, to 
avoid biased results, only 62 (32 controls and 30 AD) were used in the analysis of 
differences between healthy aged and AD brains. The data were normally 
distributed and presented as mean (SD). The gender distribution was similar in both 
groups, with females making up 67.7% of the cohort. The overall mean age of death 
was 87.43 years and it was not significantly different between AD patients and 
controls (p=0.619). Similarly, the post mortem delay and whole brain weight did not 
differ between the two groups (p=0873 and p=0276 respectively). The number of 
APOE4 carriers was significantly higher in the AD (46.7%) group than in controls 
(18.8%) (p=0.019). As expected, AD patients had significantly higher scores in all 
three pathological assessments (Thal, Braak and CERAD) than the controls 
(p<0.001), as they were assigned into groups based on these scores.  
 34 
Table 6 Cohort characteristics. (Data presented as mean (standard deviation) unless otherwise stated. P- value 
was calculated using t-test unless otherwise stated.) 
Variable Controls (n=32) AD (n=30) p-value 
Age at death [years] 87.03 (5.87) 87.83 (6.70) 0.619 
Females [n(%)] 21 (65.6) 21 (70.0) 0.713 (X2(1)=0.136)d 
Post mortem delay [hours]a 76.81 (47.97) 74.96 (37.63) 0.873 
Whole brain weight [g]b 1170.64 (118.71) 1214.33 (128.40) 0.276 
ApoE4 carrier [n(%)] 6 (18.8) 14 (46.7) 0.019 (X2(1)=5.52) 
Thal stage (amyloid 
deposition) [n(%)] 
  <0.001 (X2(5) 
=49.95)d 
0 16 (50.0) 0  
1 11 (34.4) 0  
2 3 (9.4) 3 (10.0)  
3 2 (6.3) 13 (43.3)  
4 0 7 (23.3)  
5 0 7 (23.3)  
Braak stage (neurofibrillary 
tangles) [n(%)] 
  <0.001 (X2(3)= 
57.14)d 
0 4 (12.9) 0  
1 27 (87.1) 1 (3.3)  
2 0 21 (70.0)  
3 0 8 (26.7)  
CERAD score (neuritic 
plaques) [n(%)] 
  <0.001 
(X2(3)=54.48)d 
0 17 (53.1) 0  
A 14 (43.8) 1 (3.3)  
B 1 (3.1) 17 (56.7)  
C 0 12 (40.0)  
a data available in controls n=30 and AD n=25 
b data available in control n=22 and AD n=18 
d P-value calculated using Pearson Chi-square test 
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3.5 Cognitive scores and their correlation to Braak, CERAD and Thal 
All the cognitive scores data used for the analysis in this study were obtained 
previously by Rabbitt et al. (2004). Cognitive scores were tested using a t-test (or a 
non-parametric equivalent for non-normally distributed data) to determine 
differences between the gender groups. There were no significant differences 
between males and females in any of the cognitive scores. Figure 4 shows 
longitudinal fluid intelligence score stratified by gender. To determine the 
differences in the prior cognitive measures in AD and controls, t-test for normal 
data and Mann Witney-U test for non-normal data were performed, and revealed 
that lower cross-sectional and longitudinal speed were associated with AD (p=0.022 
and p=0.008 respectively). To determine how prior cognitive scores are related to 
amyloid plaques, neuritic plaques and neurofibrillary tangles development at an 
older age, Spearman rank correlation between cognitive measures and Thal, CERAD 
and Braak scores was performed (Table 7). Test of correlation revealed that 
longitudinal fluid intelligence was significantly negatively associated with Thal (r=-
0.371, P=0.003) and CERAD (r=-0.259, p=0.042) scores. To adjust for potential 
confounders, ordinal regression test was performed. In the first model, Thal or 
CERAD were set as dependent variables and gender was set as an independent 
variable, whereas age at death and longitudinal fluid intelligence were selected as 
covariates. Ordinal regression revealed that after adjustment for sex and age at 
death, longitudinal fluid intelligence remained significantly associated with Thal 
score (p=0.013), however, the association with CERAD was no longer significant 
(p=0.103). A second model was introduced for the Thal association with 
longitudinal fluid intelligence, where APOE4 allele presence was selected as an 
independent variable in addition to the variables from the first model. Even though 
APOE4 allele presence significantly associated with Thal score (P=0.001), the 
association of longitudinal fluid intelligence remained significant after testing for 
this confounding factor (P=0.017). When the gender was removed from the model, 
as it did not associate significantly with the cognitive scores, the P value was 0.012. 
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Figure 4 Longitudinal fluid intelligence score stratified by gender.  
 
Table 7 Spearman rank correlation between the cognitive measures and AD pathology scores. The test was 
performed in both AD and controls collectively. 
Variable Thal score CERAD score Braak score 
Cross sectional fluid 
intelligence 
-0.198 -0.057 -0.037 
Cross sectional 
vocabulary 
0.053 0.068 0.048 
Cross sectional speed -0.185 -0.204 -0.196 
Cross sectional memory -0.018 -0.053 -0.053 
Longitudinal fluid 
intelligence 
-0.371** -0.259 -0.205 
Longitudinal vocabulary -0.012 0.023 -0.008 
Longitudinal speed -0.183 -0.230 -0.224 
Longitudinal memory 0.016 -0.034 -0.007 
**Correlation is significant at the 0.01 level  
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3.6 APOE protein levels in the prefrontal cortex 
The APOE protein levels were successfully measured in 62 as three samples did not 
have enough of the protein lysate for the analysis and in case of the two remaining 
samples the protein level was below the level of detection of the used method. The 
data were not normally distributed and therefore needed to be transformed using 
square root calculation to achieve normality and it is presented as square root of 
the original unit. Figure 5 shows APOE protein levels stratified by gender, values 
were not significantly different between males and females (P=0.602) 
 
 
Figure 5 APOE protein levels in the prefrontal cortex stratified by gender.  
 
3.7 APOE protein levels stratified by the disease status and APOE4 allele 
presence 
To investigate if the APOE protein levels differed in the AD compared to controls as 
well as between the APOE genotypes, two way ANOVA was performed and the 
results are shown in table 8. The test revealed that there were no significant 
differences in the brain APOE protein levels between the APOE4 carriers vs APOE4 
non carriers in either AD or controls. 
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Table 8 APOE protein levels stratified by the disease status and APOE4 allele presence/absence. 
Variable 
AD Control Effects (P-value) 
APOE4 
carrier 
APOE4 
non-
carrier 
APOE4 
carrier 
APOE4 
non-
carrier 
Disease 
group 
APOE 
Genotype 
APOE 
Genotype 
x Disease 
group 
ApoE protein 
level [√ug/mg 
protein] 
2.01 
(0.96) 
2.09 
(0.61) 
1.78 
(0.75) 
2.41 
(0.66) 
0.566 0.069 0.193 
 
3.8 Correlation of the APOE protein levels with the AD pathology scores. 
Spearman rank correlation test was performed to test whether the APOE protein 
levels associate with AD pathology scores. Neither Thal, Braak nor CERAD score 
significantly associated with the APOE protein levels (table 9).  
 
Table 9 Spearman correlation of the APOE protein levels and the AD pathology scores- Thal, Braak and CERAD. 
Variable Thal score Braak score CERAD score 
ApoE protein level -0.240 -0.183 -0.147 
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3.9 APOE protein levels and the cognitive performance.  
Pearson correlation was performed to test if the APOE protein levels were 
associated with previous cognitive scores, including fluid intelligence, vocabulary, 
speed and memory, both cross sectional as well as longitudinal. The result suggest 
that APOE protein levels in the prefrontal cortex are significantly associated with 
longitudinal fluid intelligence (R=0.265, P<0.05). No other cognitive score was 
significantly associated with APOE protein level (Table 10). 
 
Table 10 Pearson correlation of the APOE protein levels and cognitive scores 
Variable 
CS fluid 
intelligence 
CS 
vocabulary 
CS speed CS memory 
L 
intelligence 
L 
vocabulary 
L speed L memory 
APOE 
protein level 
[√ug/mg 
protein] 
0.177 0.190 0.216 -0.203 0.265* 0.217 0.188 -0.107 
*correlation was significant at P < 0.05. CS-cross sectional, L-longitudinal. 
 
Linear regression analysis was performed to further investigate the association 
between longitudinal fluid intelligence and the APOE protein levels. To account for 
other potential confounders, age at cognitive testing and APOE4 allele presence 
were also included in the model as independent variables alongside the APOE 
protein level, while longitudinal fluid intelligence was set as dependent variable. 
After adjusting for confounding factors, association of the longitudinal fluid 
intelligence with the APOE protein level remained significant (B=0.279, P=0.049). 
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3.10 TOMM40 promoter, intergenic region and APOE exon 4 
methylation 
For quality control purposes, at least eleven samples per assay were randomly 
selected and their methylation levels were measured twice on separate occasions. 
The coefficient of variation (CV = SD / mean x 100%) was calculated for each CpG 
site in a particular sample and the mean of all of the CVs for a given CpG site was 
calculated. For APOE and the IR CpGs only the CpG sites with mean CV below or 
equal 20% were included in the analysis. In case of the TOMM40 region, where the 
methylation levels were very low (mean=2.0, SD=1.1), despite the relatively high 
mean CV value for both CpG sites (24%), both CpG sites tested were included in the 
analysis. The CV values were higher in case of the hypomethylated region due to 
the limited specificity of the assay (up to 1%), therefore the variation between the 
repeated values could in fact be much lower than indicated. Eleven CpG sites in the 
APOE exon 4 region surrounding the rs429358 and rs7412 polymorphisms, two 
TOMM40 promoter region CpG sites and two intergenic region (IR) (located 
between the two genes) CpG sites were successfully assessed for methylation 
levels. The APOE exon 4 region and the IR highly methylated (APOE mean=63.3, 
SD=8.6; IR mean=57.5, SD=7.5). Whereas the TOMM40 promoter region was 
hypomethylated (mean=2.0, SD=1.1). Methylation levels were not significantly 
different between males and females at any CpG site tested (Figures 6-9) .  
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Figure 6 Mean methylation levels of the TOMM40 promoter region CpG sites stratified by gender. 
 
 
Figure 7 Mean methylation levels of the intergenic region CpG sites stratified by gender. 
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Figure 8 Mean methylation levels of the APOE exon 4 region CpG sites stratified by gender. 
 
Figure 9 Mean methylation levels of the APOE exon 4 region CpG sites stratified by gender. 
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3.11 Methylation levels stratified by APOE4 allele presence and disease 
status (AD vs controls) 
Next, it was tested whether the APOE genotype and the disease status might 
influence methylation of the locus. To do this, a two way ANOVA was performed 
with APOE genotypes, disease status set as grouping variables and DNA methylation 
at each of the CpG site across the TOMM40-APOE locus set as dependent variables 
and the results are shown in Table 11 . The test revealed that there were no 
significant differences in the brain APOE protein levels between the APOE4 carriers 
vs APOE4 non carriers in either AD or controls. None of the CpGs across TOMM40-
APOE region methylation levels were significantly different between the genotype 
groups, or between AD and controls. 
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Table 11 Brain APOE protein levels and methylation levels stratified by APOE4 allele presence (carriers vs non-
carriers) and disease status (AD vs controls). Data presented as mean (SD). 
Variable 
AD Control Effects (P-value) 
APOE4 
carrier 
APOE4 
non-carrier 
APOE4 
carrier 
APOE4 
non-carrier 
Disease 
group 
APOE 
Genotype 
APOE 
Genotype 
x Disease 
group 
TOMM40 CpG 1 
methylation * 
1.64 (1.1) 1.4 (0.5) 2.1 (1.5) 1.5 (0.8) 0.432 0.435 0.974 
TOMM40 CpG 2 
methylation  
2.5 (2.3) 2.2 (0.7) 2.8 (2.2) 2.3 (0.7) 0.857 0.919 1.00 
IR CpG 1 
methylation 
62.3 (4.9) 54.4 (6.5) 58.5 (8.0) 57.9 (8.7) 0.386 0.105 0.266 
IR CpG 2 
methylation 
61.0 (4.9) 53.2 (5.5) 56.8 (8.1) 57.1 (8.5) 0.468 0.142 0.234 
APOE CpG1 
methylation 
69.4 (6.0) 71.5 (8.4) 67.3 (18.1) 69.0 (9.3) 0.557 0.323 0.904 
APOE CpG 2 
methylation [%]a  
66.2 (6.8) 68.4 (8.9) 63.6 (17.6) 66.0 (9.3) 0.419 0.400 0.816 
APOE CpG 3 
methylation [%]a 
72.7 (6.5) 74.4 (8.6) 69.5 (18.4) 72.7 (9.9) 0.619 0.120 0.749 
APOE CpG 4 
methylation [%]a 
59.5 (6.7) 62.2 (8.5) 57.3 (16.3) 57.8 (8.4) 0.244 0.209 0.913 
APOE CpG 5 
methylation [%]a 
58.7 (6.6) 62.5 (8.9) 55.7 (16.3) 58.3 (8.4) 0.280 0.234 0.933 
APOE CpG 6 
methylation [%]a 
64.1 (7.3) 65.8 (9.8) 61.2 (16.5) 64.3 (8.4) 0.563 0.532 0.829 
APOE CpG 13 
methylation [%]b 
65.0 (13.1) 58.0 (11.3) 60.7 (20.8) 62.2 (9.9) 0.779 0.464 0.757 
APOE CpG 14 
methylation [%]b 
57.0 (12.7) 49.0 (10.5) 50.6 (18.7) 53.8 (9.7) 0.683 0.458 0.500 
APOE CpG 15 
methylation [%]b 
71.7 (10.1) 66.1 (8.3) 61.9 (19.0) 66.8 (7.2) 0.548 0.237 0.308 
APOE CpG 16 
methylation [%]b 
78.2 (11.3) 73.7 (6.8) 69.1 (19.7) 74.9 (7.9) 0.665 0.140 0.328 
APOE CpG 17 
methylation [%]b 
57.4 (11.9) 49.2 (10.1) 45.6 (17.7) 51.0 (9.9) 0.788 0.117 0.194 
adata available in n=62 
bdata available in n=52 
cdata available in n=58 
ddata available in n=66 
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3.12 Correlation of the TOMM40-APOE locus methylation with the APOE 
protein levels 
To investigate how the levels of methylation could influence the APOE protein 
expression, Pearson correlation test was performed (Table 12). This revealed that 
TOMM40 CpG site 2 methylation was negatively correlated with APOE protein level 
(r=-0.270, P=0.042). To account for confounding factors, the relationship between 
TOMM40 CpG2 methylation and APOE protein level was further investigated using 
linear regression model. APOE protein level was selected as the dependent variable 
and TOMM40 promoter region CpG2 methylation, age at death and APOE4 allele 
were set as independent variables. After adjustment for confounding factors, the 
association of TOMM40 CpG2 and the APOE protein level was no longer significant 
(B=-0.228, P=0.091).  
 
Table 12 Pearson correlation of the TOMM 40 IR and APOE DNA methylation with APOE protein levels 
Variable ApoE protein level 
TOMM40 CpG 1 methylation * -0.030 
TOMM40 CpG 2 methylation -0.270* 
IR CpG 1 methylation 0.183 
IR CpG 2 methylation 0.193 
APOE CpG1 methylation -0.084 
APOE CpG 2 methylation [%]a -0.074 
APOE CpG 3 methylation [%]a 0.066 
APOE CpG 4 methylation [%]a -0.157 
APOE CpG 5 methylation [%]a -0.156 
APOE CpG 6 methylation [%]a -0.177 
APOE CpG 13 methylation [%]b -0.175 
APOE CpG 14 methylation [%]b -0.112 
APOE CpG 15 methylation [%]b -0.115 
APOE CpG 16 methylation [%]b 0.055 
APOE CpG 17 methylation [%]b 0.004 
*correlation was significant at P<0.05 
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3.13 Correlation of the TOMM40-APOE locus methylation with AD 
pathology scores 
To investigate if the methylation levels of the tested CpG sites associate with AD 
pathology scores (Thal, Braak and CERAD), Spearman rank correlation test was 
performed (Table 13). No significant associations were found between the 
methylation levels at any other investigated CpG sites and the APOE protein level. 
Thal, Braak and CERAD scores were not significantly associated with either of the 
CpG site methylation or APOE protein level. 
 
Table 13 Spearman correlation between ApoE protein level or AD pathology and methylation levels. 
Variable Thal score Braak score CERAD score 
TOMM40 CpG 1 methylation  -0.104 -0.193 -0.127 
TOMM40 CpG 2 methylation  -0.173 -0.219 -0.210 
IR CpG 1 methylation 0.059 -0.108 -0.054 
IR CpG 2 methylation 0.021 -0.129 -0.079 
APOE CpG1 methylationa 0.024 0.070 -0.056 
APOE CpG 2 methylation [%]a  0.060 0.042 -0.037 
APOE CpG 3 methylation [%]a -0.026 0.043 -0.043 
APOE CpG 4 methylation [%]a 0.064 0.059 -0.047 
APOE CpG 5 methylation [%]a 0.074 0.064 -0.028 
APOE CpG 6 methylation [%]a 0.057 0.019 -0.060 
APOE CpG 13 methylation [%]b -0.079 -0.029 -0.109 
APOE CpG 14 methylation [%]b -0.065 -0.028 -0.125 
APOE CpG 15 methylation [%]b 0.098 0.064 -0.007 
APOE CpG 16 methylation [%]b -0.020 -0.016 -0.047 
APOE CpG 17 methylation [%]b 0.112 0.054 0.002 
adata available in n=62 
bdata available in n=52 
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3.14 Correlation of the TOMM40 - APOE locus methylation with 
cognitive scores 
Pearson correlation test was performed to investigate if methylation of the CpGs 
across TOMM40-APOE locus associate with cognitive scores and the results are 
shown in Table 14. This revealed that APOE CpG4 methylation level negatively 
correlated with longitudinal fluid intelligence (R=-0.278, P=0.046) and longitudinal 
vocabulary (R=-0.280, P=0.045), CpG 5 with cross sectional memory (R=-0.274, 
P=0.049, and longitudinal vocabulary (R=-0.288, P=0.039), whereas CpG 6 with 
longitudinal fluid intelligence (R=-0.275, P=0.047). TOMM40 CpGs 1 and 2 were 
significantly negatively associated with cross sectional fluid intelligence (R=-0.318, 
P=0.009), whereas only CpG2 with longitudinal fluid intelligence (R=-0.243, 
P=0.048).  
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Table 14 Pearson correlation between the cognitive measures and APOE protein levels and methylation levels. 
(The test was performed on both AD and control groups collectively). 
Variable Variable 
CS fluid 
intelligence 
CS 
vocabulary 
CS 
speed 
CS memory 
L 
intelligence 
L 
vocabulary 
L speed 
APOE CpG1 
a 
-0.126 -0.206 -0.037 -0.215 -0.210 -0.220 -0.130 -0.149 
APOE CpG 2 
[%]a 
-0.162 -0.225 -0.031 -0.214 -0.254 -0.231 -0.085 -0.120 
APOE CpG 3 
[%]a 
0.037 -0.196 -0.017 -0.216 -0.123 -0.219 -0.125 -0.158 
APOE CpG 4 
[%]a 
-0.211 -0.249 -0.090 -0.273 -0.278* -0.280* -0.092 -0.145 
APOE CpG 5 
[%]a 
-0.206 -0.261 -0.096 -0.274* -0.258 -0.288* -0.120 -0.145 
APOE CpG 6 
[%]a 
-0.209 -0.188 -0.044 -0.126 -0.275* -0.185 -0.088 -0.054 
APOE CpG 
13 [%]b 
-0.124 0.068 0.068 -0.006 -0.041 0.065 0.129 0.025 
APOE CpG 
14 [%]b 
-0.099 0.061 0.062 0.002 -0.001 0.078 0.116 0.037 
APOE CpG 
15 [%]b 
-0.152 0.099 -0.079 -0.072 -0.063 0.053 -0.032 0.015 
APOE CpG 
16 [%]b 
-0.180 0.108 -0.082 -0.136 -0.092 0.057 -0.080 -0.031 
APOE CpG 
17 [%]b 
-0.088 0.121 -0.043 -0.049 0.007 0.122 -0.023 0.024 
TOMM40 
CpG 1 * 
-0.318** -0.028 0.046 -0.003 -0.186 0.039 0.085 -0.018 
TOMM40 
CpG 2 
-0.318** -0.048 -0.103 0.116 -0.243* 0.076 0.119 0.049 
IR CpG 1 0.077 0.195 0.122 0.032 0.057 0.117 0.111 -0.071 
IR CpG 2 0.089 0.162 0.100 0.069 0.065 0.077 0.064 -0.029 
adata available in n=62 
bdata available in n=52 
CS-cross sectional, L-longitudinal. 
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Linear regression analysis was performed to further investigate the association 
between longitudinal fluid intelligence and the methylation levels at the CpGs that 
significantly correlated. To account for other potential confounders, age at 
cognitive testing and APOE4 allele presence were also included in the model as 
independent variables alongside the APOE protein level and TOMM40 CpG2 
methylation, APOE CpG4 and CpG6 methylation, while longitudinal fluid intelligence 
was set as dependent variable. After adjusting for confounding factors, only 
TOMM40 CpG2 methylation (B=-0.283, P=0.045) remained significantly associated 
with longitudinal fluid intelligence (Table 15). In case of the cross sectional fluid 
intelligence, linear regression model including both TOMM40 CpG sites methylation 
levels could not be performed, as their significantly correlated with each other at 
R>0.7, which caused violation of assumptions for the linear regression model. 
When only CpG1 was included in the regression analysis, together with age at 
cognitive testing and APOE4 allele presence as confounding factors, the CpG 1 
methylation level remained significantly correlated with cross sectional fluid 
intelligence (B=-0.305, P=0.014), however the overall model was not significant 
(P=0.052). Similarly in case of the Cross-sectional memory, remained significantly 
associated with APOE CpG5 methylation (B=-297, P=0.036) after adjusting for age at 
cognitive testing and APOE4 allele presence, however the overall proposed 
regression model was not significant. 
In case of the longitudinal vocabulary, linear regression could not be performed as 
the dependent variable was not normally distributed. 
 
Table 15 Multivariate linear regression analysis of longitudinal fluid intelligence with TOMM40 CpG2 
methylation and APOE protein levels including potential confounders. Model summary: P=0.022, N=48, Adj 
R2=0.188 R2=0.291 
Variable Parameter estimate (Beta) P-value 
TOMM40 CpG2 -0.283 0.045* 
APOE protein level 0.279 0.049* 
Age at cognitive testing  -0.235 0.097 
APOE CpG4 -0.351 0.416 
APOE CpG6 0.316 0.474 
ApoE4 allele 0.153 0.271 
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3.15 Immunohistochemistry staining 
The immunohistochemistry staining revealed that APOE was present in the 
prefrontal cortex sample of both AD and control brains (green on Figures 10 and 
11). However, the precise localisation of the protein APOE was not possible using 
this method, partially due to insufficient co-staining with neuronal cell markers. 
Moreover, the GFAP marker, used to identify astrocytes, indicated that the 
substantial amount of the tissue was degraded. Due to a substantial cell 
degradation in both AD and control samples, further analysis was not possible. For 
all these reasons, no differences in the IHC image between AD and control tissues 
could be identified in the present study. 
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Figure 10 Immunohistochemistry staining of the APOE protein (green) protein, GFAP (red) and merged image 
(including DAPI nuclei stain) in the prefrontal cortex tissue sections in AD (x630 magnification) 
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Figure 11 Immunohistochemistry staining of the APOE protein (green), GFAP (red) and merged image (including 
DAPI nuclei stain) in the prefrontal cortex brain tissue sections  in controls (x630 magnification) 
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4. Discussion 
The results of this project show that the number of APOE4 carriers was higher 
among AD group compared to controls, however the total APOE protein level in the 
prefrontal cortex was not significantly different between the genotype groups or 
disease groups, indicating that the APOE genotypes may modulate AD risk 
independently of the total APOE protein expression. APOE protein level did 
however, positively correlate with longitudinal fluid intelligence, but not with 
vocabulary, speed or memory, suggesting that APOE protein may have a domain 
specific effect in the prefrontal cortex. Interestingly, longitudinal fluid intelligence 
was also negatively associated with Thal score, supporting the role of the previous 
mental abilities as a risk factor in AD. TOMM40 CpG2 methylation levels were 
initially negatively correlated with APOE protein levels, however the significance 
was lost after adjustment for confounding factors. The remaining CpG sites tested 
in this study did not significantly correlate with the APOE protein expression. The 
APOE4 genotype did not have an effect on the methylation levels at any of the CpG 
sites investigated. TOMM40-APOE locus methylation was not significantly different 
between AD and control, nor did it correlate with any of the AD pathology scores. 
TOMM40 CpG2 methylation was significantly negatively correlated with 
longitudinal fluid intelligence, suggesting that the possible mechanism of domain-
specific effect of the APOE protein levels on cognition may be related to altered 
methylation levels in the regulatory region.  
 
4.1 Differences between AD and controls 
The number of the APOE4 carriers was significantly higher in the AD cases 
compared to controls. It aligns with previous findings, as it has been widely 
established that carrying at least APOE4 allele significantly increases the risk of 
sporadic LOAD (Corder et al., 1993; Blacker et al., 1997). There are multiple 
proposed mechanisms by which APOE4 allele could increase the risk of the AD. For 
instance, APOE 4 may enhance amyloid plaque formation, by forming stable 
complexes with Aβ (Strittmatter et al., 1994; Cho et al., 2001) or reduce Aβ 
clearance via dysregulation of astrocyte colocalisation, which reduces their ability 
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to clear Aβ (Koistinaho et al., 2004). The E4 allele may also contribute to AD 
pathogenesis independently of AB. It may for example, enhance tau 
phosphorylation (Cruchaga et al., 2013) or cause neurotoxicity via mitochondrial or 
cytoskeleton disruption The partially degraded APOE4 particles may also 
accumulate in the neurofibrillary tangles (P. B. Jones et al., 2011; Huang et al., 
2001).  
However, the presence of the APOE4 allele is not sufficient nor is it necessary for 
the disease development and there must be other mechanisms involved in the AD 
pathogenesis. The other risk factors may include different genes that act in 
combination or separately from APOE genotype. There are also certain 
environmental determinants that have been identified as potential risk factors. This 
research hypothesised that these may affect gene methylation and therefore the 
protein expression (acting in line with or separately from the genotype). 
 
4.2 APOE protein levels in AD compared to controls 
In the present research, AD and the APOE4 allele presence did not have a significant 
effect on the APOE protein levels, nor did the interaction between the two 
variables. Furthermore, APOE protein levels did not significantly correlate with any 
of the AD pathology scores (Braak, Thal and CERAD). However, only the total APOE 
levels were measured, not the levels of the specific APOE isoforms. This could mean 
that the overall APOE levels do not significantly affect the AD pathology 
development and the effect is isoform-specific. Alternatively, it could be the case 
that the overall APOE protein level in the brain does not influence AD whatsoever. 
However, it is unlikely, as previous research suggested that APOE has a 
neuroprotective role (Toledo et al., 2014), aiding Schwann cells remyelination and 
axons recovery upon tissue injury (Huang and Mahley, 2014), indicating that 
decreased levels could lead to aggravated neurodegeneration and cognitive 
decline. There is also a number of other properties of the APOE2 and APOE3 that 
might be protective of AD. Multiple possible mechanisms of the APOE4 contribution 
to the AD pathology have been presented, and a number of studies implicated 
altered APOE protein levels directly in the brain or CSF as a contributor to the 
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pathology. Previous findings show that AD would typically be associated with 
decreased APOE protein levels in the frontal cortex and hippocampus (Beffert et al., 
1999; Bertrand et al., 1995). Again, it could be also a case that this study lacks 
statistical power to detect an association where it in fact present. Sporadic AD is a 
heterogeneous disease and various factors contribute to their pathogenesis. In 
certain circumstances these factors might have a more pronounced effect, in others 
they might only confer a small change. Moreover, the protein levels were only 
measured in prefrontal cortex and there could be more pronounced differences in 
the different brain areas such as hippocampus, which is predominantly responsible 
for the episodic memory, the first cognitive feature to be affected by AD.  
 
4.3 APOE protein expression across APOE genotypes 
The APOE genotypes were in the Hardy - Weinberg equilibrium and the observed 
allele frequencies were not significantly different from expected for the British 
population according to the 1000 genome’s project (The Genomes Project, 2015). 
Even though, the study sample was an adequate representation of the allele 
distribution in the population, due to relatively small sample size and relatively low 
minor allele frequencies for both genotypes, the data was stratified on the basis of 
the APOE4 allele presence or absence alone, rather than according to the individual 
genotypes. If the homozygous genotypes would be compared, it could give an 
insight into how each allele affects gene methylation and expression individually; 
however, there were only two homozygous samples for the APOE2 and APOE4 
genotypes, therefore the participants were grouped into APOE4 carriers and APOE4 
non-carriers. 
APOE protein levels were not significantly different between APOE4 carriers and 
non APOE4 carriers. This could mean that the APOE genotype does not affect 
protein expression in the brain prefrontal cortex. These findings differ from the 
previous publications, as other studies suggest that APOE genotype could affect 
APOE protein expression. APOE4 allele has been previously associated with 
decreased APOE protein levels in vitro on the human astrocytoma cell culture 
(Riddell et al., 2008), and in vivo in the mice brains as well as post mortem human 
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frontotemporal lobe brain samples (Bray et al., 2004). However, the absolute levels 
of the APOE3 were similar between carriers of E3/3 and E3/4 genotype, suggesting 
that the overall decrease in the APOE protein levels could be due to the reduction 
in the E4 isoform. According to Riddell et al., APOE4 has a shorter half-life and is 
degraded at a higher rate than APOE3, which might be the cause for overall 
decreased APOE protein levels in the APOE4 carriers (Riddell et al., 2008). The 
reason for the differences in findings could be the methodology differences 
between the studies, as the mouse and astrocytoma cell culture study only 
investigated the differences between the homozygotes for each allele, whereas in 
this study, both homozygous and heterozygous E4 allele carriers were compared 
against non-carriers. There could be also differences in the genotype effect 
between human samples and mouse or in vitro models. Alternatively, it could be 
the case that the present findings could be a false null due to the low sample size. 
Furthermore, an isoform-specific APOE protein quantification would allow to assess 
the effect of the individual genotypes more accurately. 
 
4.4 Allele specific APOE methylation 
It was hypothesised that the APOE exon 4 region methylation level would differ 
between the genotypes, especially because the rs7412 (C->T) removes a CpG site, 
and the rs429358 (T->C) creates an extra CpG site. This study, however, did not find 
any significant difference between the methylation levels of the TOMM40 
promoter region, APOE exon 4 CpG island or the intergenic region between APOE 
genotype groups. Again, a further stratification between the individual genotypes 
or best, investigation of differences between the homozygous samples could 
provide a better understanding on whether and how the APOE polymorphisms 
influence the gene methylation. There was one previous study, which suggested 
that the APOE exon 4 CpG island methylation was significantly higher in the frontal 
lobe among the carriers of E3/E4 genotypes compared to the E3/E3 carriers 
(Foraker et al., 2015). However the effect was only seen in the controls but not in 
the AD and the sample size was relatively small (n=25). Other previous studies that 
investigated the APOE locus methylation did not observe any genotype effect on 
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the methylation levels (Karlsson et al., 2018) or they did not investigate the 
difference in methylation between different genotypes (Shao et al., 2018; Tulloch et 
al., 2018). Therefore, further research, preferably in a larger cohort is necessary to 
fully understand how different APOE alleles may influence the methylation. 
Multiple environmental factors, such as diet, exercise, smoking, long term stress 
exposure, that were not available for this cohort may influence the gene 
methylation (Abdul et al., 2017; Lee and Pausova, 2013). Accounting for these, for 
instance by stratifying the cohort according to theirs smoking status, could help to 
understand how the genotype may affect the methylation levels in combination 
with these confounders. The APOE4 allele is thought to provide an advantage in the 
environments where the food availability is scarce, by increasing the cholesterol 
absorption from the intestine (Corbo and Scacchi, 1999). Therefore, in populations 
where the diet is high in calories and rich in saturated fat and refined sugar, 
carrying the E4 allele might be a disadvantage.  
There are three possible mechanisms in which a SNP can affect gene methylation 
and expression: influence the methylation levels leading to altered gene expression, 
affect the gene expression which subsequently alters the methylation levels or it 
could affect both methylation and gene expression independently of each other (M. 
J. Jones et al., 2013). If a polymorphism alters or interferes with a transcription 
factor binding site, it is likely that it would affect both gene expression and 
methylation independently (Gutierrez-Arcelus et al., 2013). As the transcription 
factors typically bind at the promoter region, it might be a case that there are no 
transcription factor binding sites in the exon 4 of the APOE gene, where the 
investigated SNPs are located and therefore, the APOE genotypes do not directly 
influence the levels of gene expression or methylation.  
 
4.5 Brain APOE protein level and TOMM40-APOE region methylation 
association with AD pathology 
Epigenetics could be an important aspect of the AD pathogenesis, especially 
considering that AD is very heterogeneous and it may exhibit very different clinical 
presentation even in patients with very similar genetic background (Yokoyama et 
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al., 2017). A good example of this could be a study on monozygotic twins, that 
showed a significant reduction of the methylation levels in the frontal cortex of the 
AD twin compared to the twin that did not develop the disease (Mastroeni et al., 
2009). Although, other studies have suggested that individuals with AD tend to 
have higher global methylation in the prefrontal cortex than controls (Coppieters et 
al., 2014; Rao et al., 2012).  
In the present study, methylation of the investigated TOMM40-APOE region in the 
prefrontal cortex did not significantly correlate with the APOE protein expression, 
nor did it correlate with any of the AD pathology scores. This area of research is 
quite novel and not many previous studies investigated the methylation of this 
specific locus in AD. A study that investigated the methylation of a number of AD-
related genes in the temporal lobe, parietal lobe and the cerebellum did not find a 
significant difference in the APOE gene methylation between the AD and controls 
(Iwata et al., 2014). Another study showed a significantly higher APOE promoter 
methylation in the prefrontal cortex samples of the AD patients compared to 
controls (Wang et al., 2008). However, likewise in this study, there was no 
significant difference in the exon 4 CpG island methylation levels between AD and 
controls (Karlsson et al., 2018). They did not specify which individual CpG sites in 
that region they investigated. Interestingly, the APOE exon 4 CpG island was 
hypermethylated, and the methylation levels across the regions were close to 100% 
in majority of cases. The APOE exon 4 CpG island was also hypermethylated in the 
present cohort, however the levels were much lower and there was more variation 
between each CpG sites ranging from 52-75% methylation. Although, there could 
be variation in methylation levels among different population, as they only 
investigated a small number of samples (n=34) and to account for these variations 
in the epigenetic studies, preferably a larger cohort would be required. It is worth 
mentioning that they also used a different method for the methylation levels 
quantification (MALDI-TOF), which could also be a possible cause for differences. 
There is, however, some evidence that the APOE exon 4 CpG island might be 
differently methylated in AD. For instance Foraker et al. (2015) found significantly 
reduced methylation in the hippocampus and frontal lobe but not the cerebellum 
of the AD brains, with the highest difference being in the frontal lobe. This finding 
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differs significantly from our findings however, Foraker et al. only analysed 25 
samples and there could be covariates, such as cholesterol levels that were not 
accounted for, that might affect the result independently of the AD, that would 
influence the trend. Notably, they also used bisulphite pyrosequencing to measure 
the methylation levels and the mean methylation of the prefrontal cortex was 77%, 
which is closer to our findings, however significantly lower than in the Wang’s 
study. These variations suggest that preferably a larger cohort would be required to 
investigate the effect of methylation on AD, especially if the results were to be 
applied to wider populations, and used as potential diagnostic/prognostic factors, 
as there may be different environmental determinants that affect methylation 
levels in the specific populations that would ideally need to be accounted for. One 
study investigated the APOE exon 4 CpG island methylation in AD and the Lewy 
Body Dementia (LBD) (Tulloch et al., 2018) as APOE4 has been also implicated as a 
risk factor in LBD (Lane et al., 2009; Bras et al., 2014; Keogh et al., 2016). They 
found no significant differences in the methylation levels in the cerebellum, 
however there was a significant reduction of the methylation levels in the 
prefrontal cortex of the LBD brains. Interestingly, the methylation levels were even 
lower in the brains that exhibited both LBD and AD pathological changes, which is 
an intriguing finding, considering that both diseases share some clinical features 
and the rate of cognitive decline is more rapid if both AD and LBD occur 
concomitantly (Kraybill et al., 2005; Chung et al., 2015). In contrast to this study, 
neither Wang’s, nor Tulloch’s studies measure the APOE protein levels in the brains 
to compare if and how the methylation levels would affect the protein expression 
in the specific brain regions. 
Two previous studies also investigated the extended APOE locus methylation in 
context of AD (Shao et al., 2018; Karlsson et al., 2018). According to Karlsson et al. 
(2018) findings, increased level of the APOE promoter methylation raises the odds 
of developing dementia and AD but not cardiovascular disease. Although, the 
methylation levels were not dependent on the APOE genotype. The study was 
conducted on a larger cohort of 447 Swedish twins and they adjusted the results for 
age, sex, education level, smoking and relatedness among twins and this study has 
a lot of strengths in terms of design. However they measured the levels of 
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methylation in the blood samples, which may differ from that in the brain, as it has 
previously found that the methylation levels of this region would vary across 
different tissue types (Shao et al., 2018). Similarly, Shao et al. found a significant 
association of the TOMM40-APOE locus methylation and AD. Their findings indicate 
that TOMM40-APOE locus might be differently methylated in AD brains but not in 
the peripheral blood. Moreover, APOE, but not TOMM40 methylation levels 
differed across different tissue types in both AD and controls. The proposed 
mechanism of action of the altered TOMM40-APOE methylation levels in AD was 
via the regulation of the APOE mRNA expression. They suggested that methylation 
of the TOMM40 promoter region is correlated with both TOMM40 and APOE gene 
expression and at certain CpG sites the correlations were of opposing nature: 
negative with the TOMM40 gene and positive with the APOE gene. Furthermore, 
they found that another CpG site in the TOMM40 promoter was associated with 
APOE mRNA expression, although the association was negative in controls and 
positive in AD. They did not, however measure the APOE protein levels in their 
study, which may be the cause for the differences in the findings, as this study 
measured APOE protein levels, but not mRNA levels. In the present study there was 
also a negative correlation of one of the TOMM40 promoter region CpG sites with 
APOE protein expression, however we tested the association across the whole 
cohort rather than separately in AD and control groups and the significance was lost 
after adjusting for age at death and APOE4 allele presence. All these findings 
indicate that TOMM40-APOE locus methylation might affect the AD pathology via 
altering APOE expression, however the specific mechanisms of these associations 
remain unknown. To be able to conduct epigenetic studies with a higher statistical 
power, ideally a larger cohort should be used, which would allow for appropriate 
stratification and perhaps this would help to detect the true associations. 
 
4.6 Brain APOE protein levels, cross sectional and longitudinal cognitive 
scores and how do they relate to AD pathology scores 
Our findings suggest that APOE protein levels in the prefrontal cortex positively 
correlate with longitudinal fluid intelligence (R=0.265, P<0.05) but not with the 
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cross sectional fluid intelligence. Although, the cognitive tests were performed 
earlier in their life and cross sectional intelligence could have changed by the time 
of death and sample collection. Therefore, the longitudinal cognition would be a 
better indicator of the overall cognitive performance for this type of correlation. 
Similarly to our findings, previous research suggested that APOE protein in the 
cerebrospinal (CSF) fluid may associate with longitudinal cognitive decline (Toledo 
et al., 2014).They proposed a hypothesis that increased APOE2 and APOE3 
expression in the CSF might be a protective response to a brain injury and 
accumulation of APOE protein in the brain may stimulate neuronal regeneration 
(Toledo et al., 2014). The AOE protein levels did not, however, correlate with speed, 
memory or vocabulary. This could mean that APOE has a domain-specific effect in 
the particular parts of the brain, especially considering that dorsolateral prefrontal 
cortex is the main part of the brain involved in the fluid intelligence processes. It 
has been previously found that APOE4 carriers that were also carriers of the 
Cathepsin D (CTSD) T genotype scored significantly lower in the fluid intelligence, 
but the APOE genotype did not have an effect when investigated separately (Payton 
et al., 2006). As APOE 4 isoform has been previously associated with decreased 
expression, it could suggest that APOE genotype could influence cognitive decline 
by altering APOE protein expression in the carriers of CTSD T genotype.  
Interestingly, methylation of the TOMM40 CpG promoter region negatively 
correlated with longitudinal fluid intelligence. Initially, there was also a negative 
correlation between the TOMM40 CpG methylation and the APOE protein levels, 
which could provide an insight into the mechanism of the association between the 
TOMM40 methylation and longitudinal fluid intelligence (increased TOMM40 
promoter methylation® decreased APOE protein expression ® decline of the fluid 
intelligence). However, the association of the TOMM40 methylation with APOE 
protein levels was no longer significant after adjustment for confounding factors. 
Recent studies suggested that the TOMM40 promoter region methylation may 
correlate with APOE protein expression in the hippocampus and cerebellum 
(Karlsson et al., 2018; Shao et al., 2018) . Nevertheless, these were only exploratory 
studies and the associations differed across the CpG sites. Moreover in one of the 
studies the nature of the correlation was opposite in the AD and controls (Shao et 
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al., 2018), therefore it would be difficult to establish what would be the overall 
effect of the methylation on the APOE protein expression in both groups 
collectively.  
Although, the present study did not find any significant association of the APOE4 
genotype APOE protein levels in the prefrontal cortex and the levels did not 
significantly differ between AD and control brains, there are numerous studies that 
showed decreased levels of APOE protein in the AD brains and CSF and with a 
significant effect of the APOE4 allele (Lehtimaki et al., 1995; Merched et al., 1997; 
Bekris et al., 2010). As this study shows that the increased APOE protein levels did 
associate with better longitudinal fluid intelligence collectively in AD and controls, it 
may suggest that APOE could influence cognition independently of the AD 
development. However, longitudinal fluid intelligence also negatively correlated 
with Thal score. This is an interesting finding, as previous mental capabilities have 
been implied as a risk factor in AD (Mayeux, 2003; Mortimer et al., 2003). All these 
findings suggest that epigenetic TOMM40- APOE regulation may influence cognitive 
abilities via regulation of APOE expression or via independent mechanisms and thus 
translate into AD pathology development in later life. Therefore, it is imperative to 
understand the mechanisms that regulate the APOE protein expression and may be 
potential therapeutic targets for the AD modulation. Due to loss of function and/or 
gain of toxic function effect of the APOE4 allele, understanding how different alleles 
are transcriptionally regulated might be important in the early diagnosis and 
disease progression prediction. 
 
4.7 Limitations and future recommendations 
4.7.1 Limitations 
This study has several strengths, including quantification of APOE protein levels in 
the brain as well as longitudinal cognitive scores that allow an insight into the AD 
risk factors and domain specific effect of APOE genotypes and the protein levels. 
Although, there are also several limitations to this study. For instance, a technical 
limitation is the method used for the methylation analysis, as bisulphite 
pyrosequencing performs best with very short sequences. In the runs involving a 
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longer sequence, the signal decreased or was lost towards the end of the sequence. 
To be able to determine methylation levels of the whole APOE gene regulatory 
region would require designing multiple assays that would be very costly and time 
consuming, which would significantly exceed the budget and time-scale of this 
project. Also, designing PCR and sequencing primers in the CpG-dense gene regions, 
as in case of the APOE exon 4 CpG island, was challenging, due to the possibility of 
unspecific binding in these areas or issues with primer compatibility. For this 
reason, the assay required a number optimization steps and more than one set of 
primers needed to be tested until the optimal results were achieved. If this method 
was to be further optimised for the purpose of analysis of APOE exon 4 region, to 
achieve sufficient yield in the PCR product and thus possibly higher signal in the 
pyrosequencing assay, it would be recommended to elute half of the volume of the 
of the converted bisulphite DNA than it was used in this study.  
Another limitation occurred with the immunohistochemistry staining of the tissue 
sections. Examining the freshly cut sections under microscope, revealed that in 
certain samples the tissue was partially degraded and vacuolized. Possible cause of 
the damage could be sample handling at the brain centre, such as extended time 
between tissue collection and freezing. 
With multifactorial diseases such as dementia and AD, individual SNPs or 
methylation of small gene region may confer only a modest influence on the 
pathology and the diseases risk, therefore, to avoid type II error larger sample size 
would be allow to detect whether there are any true associations. Due to a low 
sample size this study may lack power to detect any significant associations.  
As a result of a significant post mortem delay, the levels of mRNA were very low 
and of poor quality, therefore, this study did not measure mRNA levels which could 
allow to give an insight into how APOE methylation directly affects the level of 
mRNA transcripts and which CpG sites may have a significant effect.  
 
4.7.2 Future recommendations 
Performing an isoform-specific high-sensitivity ELISA, would help to gain a better 
understanding of how different APOE alleles influence AD pathology. Going 
forward, an investigation of the methylation levels across the whole TOMM40-
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APOE region, especially in the promoter regions could help to identify possible 
single CpG sites or islands that may have an effect on the protein expression and 
thus AD pathology. Furthermore, comparing the levels of the APOE mRNA and the 
transcription factors across the genotypes and AD pathology stages as well as 
correlating that to the methylation levels could provide more detailed insight on 
the allele-specific gene regulation in AD. As the mRNA production stops at the time 
of death, measuring the mRNA levels in blood and CSF could provide a better 
understanding of how different APOE alleles affect the gene expression and how 
APOE gene is methylated across different tissue types. To expand on the current 
research, the future studies could also measure levels of cholesterol in the brain. 
Comparing the cholesterol levels between different alleles and AD pathology 
stages, could provide an insight into the mechanisms by which APOE alleles may 
modulate AD development. 
In regards to immunohistochemistry staining, co-staining with neuron specific 
antibodies (NEFM), and oligodendrocytes antibodies (CNP) would allow localisation 
of the APOE protein in the brain tissue. Furthermore, staining with isoform-specific 
APOE antibodies and comparing in the heterozygous samples could provide an 
insight into the localisation and ratio of the specific isoforms. 
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5. Conclusion 
Sporadic AD is a complex disorder, displaying heterogeneous pathogenesis and 
numerous genetic variants together with environmental factors may interact to 
influence the diseases risk.  
 
TOMM40-APOE locus methylation might influence the risk of AD by modulating 
APOE protein expression directly in the brain. Although, this study did not find any 
association of TOMM40-APOE region methylation, APOE protein expression and the 
AD pathology, there are some previous studies that suggest that this region is 
differently methylated in AD disease and the effect might be linked to APOE 
genotype and lead to altered APOE expression.  
 
We found that APOE protein levels in the prefrontal cortex positively correlate with 
longitudinal fluid intelligence, which also correlates with Thal score. These findings 
indicate that APOE protein may have domain - specific effect on longitudinal 
cognition and therefore influence the AD risk possibly by affecting the deposition of 
amyloid plaques. 
 
Further studies, preferably including a larger sample size are necessary to fully 
establish how methylation of TOMM40-APOE locus regulates APOE protein 
expression in the brain and how this influences the risk of AD.  
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